Brain monoamines are involved in many of the same processes affected by neuropsychiatric disorders and psychotropic drugs, including cannabinoids. This study investigated in vitro effects of cannabinoids on the activity of monoamine oxidase (MAO), the enzyme responsible for metabolism of monoamine neurotransmitters and affecting brain development and function. The effects of the phytocannabinoid Delta(9)-tetrahydrocannabinol (THC), the endocannabinoid anandamide (N-arachidonoylethanolamide [AEA]), and the synthetic cannabinoid receptor agonist WIN 55,212-2 (WIN) on the activity of MAO were measured in a crude mitochondrial fraction isolated from pig brain cortex. Monoamine oxidase activity was inhibited by the cannabinoids; however, higher half maximal inhibitory concentrations (IC(50)) of cannabinoids were required compared to the known MAO inhibitor iproniazid. The IC(50) was 24.7 micromol/l for THC, 751 micromol/l for AEA, and 17.9 micromol/l for WIN when serotonin was used as substrate (MAO-A), and 22.6 micromol/l for THC, 1,668 micromol/l for AEA, and 21.2 micromol/l for WIN when phenylethylamine was used as substrate (MAO-B). The inhibition of MAOs by THC was noncompetitive. N-Arachidonoylethanolamide was a competitive inhibitor of MAO-A and a noncompetitive inhibitor of MAO-B. WIN was a noncompetitive inhibitor of MAO-A and an uncompetitive inhibitor of MAO-B. Monoamine oxidase activity is affected by cannabinoids at relatively high drug concentrations, and this effect is inhibitory. Decrease of MAO activity may play a role in some effects of cannabinoids on serotonergic, noradrenergic, and dopaminergic neurotransmission.

Department of Psychiatry 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Ke Karlovu 11 120 00 Prague 2 Czech Republic

Zobrazit více v PubMed

AAPS PharmSci. 2000;2(1):E8 PubMed

Pharmacol Rev. 2006 Sep;58(3):389-462 PubMed

Physiol Rev. 2009 Jan;89(1):309-80 PubMed

Jpn J Pharmacol. 1999 Sep;81(1):115-21 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 1999 May;359(5):428-31 PubMed

Br J Pharmacol. 2006 Jan;147 Suppl 1:S287-96 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2006 Jan;372(4):313-7 PubMed

Biochem Pharmacol. 1989 Oct 1;38(19):3297-304 PubMed

Addict Biol. 2007 Jun;12(2):158-66 PubMed

Mol Psychiatry. 2007 Jun;12(6):522-43 PubMed

Neuropharmacology. 2008 Jan;54(1):51-7 PubMed

Neurochem Res. 2005 May;30(5):597-601 PubMed

Toxicol Appl Pharmacol. 2008 Apr 1;228(1):8-16 PubMed

Br J Pharmacol. 1971 Jun;42(2):308-10 PubMed

Br J Pharmacol. 1997 Jul;121(5):901-12 PubMed

Neuropsychopharmacology. 2007 Sep;32(9):2036-45 PubMed

Am J Obstet Gynecol. 1999 Aug;181(2):491-7 PubMed

Proc Natl Acad Sci U S A. 1988 Jul;85(13):4934-8 PubMed

Curr Drug Abuse Rev. 2009 Jan;2(1):51-75 PubMed

Toxicol Appl Pharmacol. 1977 May;40(2):347-54 PubMed

JAMA. 2009 Mar 18;301(11):1165-6 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):61-72 PubMed

Arch Int Physiol Biochim. 1982 Apr;90(1):15-20 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):516-24 PubMed

Gen Physiol Biophys. 1996 Feb;15(1):51-64 PubMed

Invest Ophthalmol Vis Sci. 1982 Apr;22(4):482-5 PubMed

Gen Pharmacol. 1984;15(2):171-4 PubMed

Biochem Pharmacol. 1981 Dec 15;30(24):3329-32 PubMed

Eur J Pharmacol. 2006 Mar 18;534(1-3):83-8 PubMed

J Anal Toxicol. 2005 Nov-Dec;29(8):842-3 PubMed

Biochem Pharmacol. 2001 Jun 1;61(11):1357-67 PubMed

Neuropsychopharmacology. 2005 Mar;30(3):508-15 PubMed

Biochem Pharmacol. 2000 Jun 15;59(12):1611-21 PubMed

Endocr Metab Immune Disord Drug Targets. 2008 Sep;8(3):220-30 PubMed

Biochemistry. 2009 May 26;48(20):4220-30 PubMed

J Med Chem. 1998 Nov 19;41(24):4861-72 PubMed

Trends Pharmacol Sci. 2009 Sep;30(9):484-93 PubMed

J Neurosci. 2007 Jan 24;27(4):791-5 PubMed

Neural Plast. 2007;2007:52908 PubMed

Mini Rev Med Chem. 2003 Mar;3(2):129-36 PubMed

Arch Biochem Biophys. 1978 Dec;191(2):714-8 PubMed

Neuro Endocrinol Lett. 2006 Jun;27(3):307-13 PubMed

Alcohol Clin Exp Res. 1994 Oct;18(5):1114-20 PubMed

Nat Rev Neurosci. 2006 Apr;7(4):295-309 PubMed

Res Commun Chem Pathol Pharmacol. 1977 Jul;17(3):471-80 PubMed

Eur J Neurol. 2006 Nov;13(11):1170-85 PubMed

J Med Chem. 1998 Oct 22;41(22):4207-15 PubMed

Ther Drug Monit. 1993 Dec;15(6):527-32 PubMed

Gen Pharmacol. 1996 Jul;27(5):773-8 PubMed

Biochem Biophys Res Commun. 2007 Dec 7;364(1):131-7 PubMed

CNS Spectr. 2008 Oct;13(10):855-70 PubMed

Biochem Pharmacol. 1976 May 15;25(10):1133-8 PubMed

Pharmacol Rev. 2002 Jun;54(2):161-202 PubMed

Neurosci Biobehav Rev. 2008 Aug;32(6):1152-60 PubMed

J Pharm Pharmacol. 2001 Aug;53(8):1125-30 PubMed

J Med Chem. 1996 Jan 19;39(2):471-9 PubMed

Neurochem Int. 2004 Jun;44(7):529-38 PubMed

Cell Mol Life Sci. 2006 Jul;63(14):1597-613 PubMed

Biochem Pharmacol. 1973 Dec 1;22(23):3099-108 PubMed

Biochem Pharmacol. 1976 Feb 15;25(4):377-8 PubMed

J Neural Transm (Vienna). 2008 Dec;115(12):1673-9 PubMed

J Pharm Sci. 2004 May;93(5):1176-84 PubMed

Life Sci. 1988;42(21):2131-6 PubMed

Pharmacol Res. 2007 Nov;56(5):360-6 PubMed

FEBS Lett. 1996 Sep 16;393(2-3):231-5 PubMed

Biochem Pharmacol. 1986 Apr 15;35(8):1381-7 PubMed

Pharmacol Biochem Behav. 1991 Nov;40(3):617-23 PubMed

Neuropharmacology. 2009 Sep;57(3):208-18 PubMed

J Biol Chem. 1951 Nov;193(1):265-75 PubMed

J Med Chem. 2005 Aug 11;48(16):5059-87 PubMed

Different Effects of SSRIs, Bupropion, and Trazodone on Mitochondrial Functions and Monoamine Oxidase Isoform Activity

Age-Dependent Alterations in Platelet Mitochondrial Respiration

Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism-In Vitro Study

In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity

Cannabinoid-Induced Changes in the Activity of Electron Transport Chain Complexes of Brain Mitochondria